Zinc-finger protein 143 (ZNF143) is a human homolog of Xenopus transcriptional activator staf that is involved in selenocystyl tRNA transcription. We previously showed that ZNF143 expression is induced by treatment with DNA-damaging agents and that it preferentially binds to cisplatin-modified DNA. In this study, the potential function of ZNF143 was investigated. ZNF143 was overexpressed in cisplatin-resistant cells. ZNF143 knockdown in prostate cancer caused increased sensitivity for cisplatin, but not for oxaliplatin, etoposide and vincristine. We also showed that ZNF143 is associated with tumor suppressor gene product p73 but not with p53. p73 could stimulate the binding of ZNF143 to both ZNF143 binding site and cisplatin-modified DNA, and modulate the function of ZNF143. We provide a direct evidence that both Rad51 and flap endonuclease-1 are target genes of ZNF143 and overexpressed in cisplatin-resistant cells. Taken together, these experiments demonstrate that an interplay of ZNF143, p73 and ZNF143 target genes is involved in DNA repair gene expression and cisplatin resistance.
Introduction
Cisplatin is an important chemotherapy drug used in the treatment of many solid tumors (Zamble and Lippard, 1995; Cohen and Lippard, 2001) . Its major limitation is the development of resistance (Torigoe et al., 2005) . The mechanisms of cisplatin resistance are not completely understood. Cisplatin resistance is influenced by many factors, which affect intracellular drug accumulation (Fujii et al., 1994) , levels of cellular thiols (Tew, 1994) and DNA repair activity (Chaney and Sancar, 1996) . Drug-induced responses are mediated by transcription factors and include DNA damage signals that lead to the induction of apoptosis in tumor cells by cisplatin (Torigoe et al., 2005; Kohno et al., 2005) . Loss of p53 function confers resistance in cancer cell lines (Keshelava et al., 2001) . Further, p73 overexpression is associated with cisplatin resistance (Vikhanskaya et al., 2001) . Thus, molecular links between transcription factors and drug resistance promises to provide the foundation for novel molecular targeted chemotherapy (Kohno et al., 2005) . We previously reported that transcription factor, Y-box binding protein 1 (YB-1), binds preferentially to cisplatin-modified DNA (Ise et al., 1999) and YB-1 expression is upregulated in cisplatin resistance cells (Ohga et al., 1996; Kohno et al., 2003; Kuwano et al., 2004) .
We identified the cisplatin-inducible genes such as activating transcription factor 4 (ATF4) (Tanabe et al., 2003) and Mitochondrial ribosomal protein S11 (MRP S11) (Ishiguchi et al., 2004) using differential display (Murakami et al., 2001) . ATF4 is upregulated in cisplatin-resistant cells and its expression correlates with cisplatin resistance in lung cancer (Tanabe et al., 2003) . Analysis of the MRP S11 promoter region gene revealed that the zinc-finger transcription factor zinc-finger protein 143 (ZNF143) is involved in the cisplatin induction. ZNF143 is a human homolog of Xenopus Staf (Myslinski et al., 1998) , and is involved in the transcriptional regulation of small nuclear RNA (snRNA) and snRNA-type genes by RNA polymerase II or III (Schaub et al., 1997; Rincon et al., 1998) . It is induced by DNA-damaging agents and binds preferentially to cisplatin-modified DNA (Ishiguchi et al., 2004) . In this study, we show that ZNF143 is upregulated in cisplatin-resistant cells. p73 interacts with ZNF143 and promotes the binding of ZNF143 to both ZNF143 binding site and cisplatin-modified DNA. And we also show that ZNF143 plays an important role in the control of DNA repair gene expression.
Results

ZNF143 is upregulated in cisplatin-resistant cell lines
ZNF143 gene expression was shown to be increased in cisplatin-resistant cells in comparison with the parental cells ( Figure 1a ). Western blotting analysis revealed that ZNF143 protein was overexpressed in cisplatin-resistant cells when sonicated nuclear fractions were loaded ( Figure 1b) . However, inverse result was obtained when eluted nuclear extracts using salt buffer were loaded (data not shown), suggesting that ZNF143 may be tightly bound to chromatin in cisplatin-resistant cells.
The effects of ZNF143 expression on cisplatin sensitivity To determine whether ZNF143 protein plays a role in cisplatin sensitivity, we inhibited its expression using small interfering RNA (siRNA) knockdown. Western blotting analysis showed that three kinds of ZNF143 siRNAs specifically downregulated ZNF143 expression in comparison with control siRNA treatment (Figure 2a ). The effect of ZNF143 inhibition on clonogenic survival was also assessed (Figure 2b ). Downregulation of ZNF143 expression by three kinds of siRNAs rendered cell sensitive to cisplatin (Figure 2b, left upper panel) . Specific inhibition of ZNF143 had significantly sensitized PC3 cells to cisplatin, but not to oxaliplatin, etoposide and vincristine (Figure 2b ). Further, downregulation of ZNF143 could partially reverse the cisplatin resistance of P/CDP6 cells (Figure 2c and d) .
Association of p73 with ZNF143
As damage to DNA increases the nuclear accumulation of tumor suppressor gene products, we next investigated the interaction of ZNF143 with p53 and p73. We employed transient transfection using both 3 Â Flag-ZNF143 and hemagglutinin (HA)-p53 or HA-p73-expressing plasmids. The complexes immunoprecipitated with anti-Flag antibody contained HA-p73 (Figure 3a ), but not HA-p53 (Figure 3c ). And we also verified that the complex contained 3 Â Flag-ZNF143 when HA-p73 was reciprocally immunoprecipitated using HA antibody (Figure 3b ).
p73 stimulates the DNA binding of ZNF143 We previously reported that ZNF143 preferentially binds to cisplatin-modified DNA (Ishiguchi et al., 2004) . To examine the effect of p73 on ZNF143 binding to oligonucleotide containing ZNF143 binding site of human U6 RNA promoter and cisplatin-modified DNA, we performed electrophoretic mobility shift assay (EMSA). Both glutathione-S-transferase (GST) and GST-p73 could not bind to both ZNF143 binding site ( Figure 4a , left panel) and cisplatin-modified DNA (Figure 4b , left panel). The DNA binding of ZNF143 was significantly enhanced by GST-p73 in a dosedependent manner, but not by control GST. However, p73 did not alter the electrophoretic mobility of the ZNF143 complex formed with DNA.
Potential ZNF143 target genes for DNA repair pathways More than 150 genes for DNA repair pathways were identified and listed (Wood et al., 2005) . A 19 bp consensus sequences for staf binding site was reported (Schaub et al., 1997; Rincon et al., 1998) and was used in a computer search of the human genome database. Initially, we surveyed and selected the putative staf binding sites, which show more than 70% homology in the promoter region containing 1000 bp upstream from the transcriptional start site. Among about 150 DNA repair genes, the putative binding sites were found in the promoter region of 78 genes. As C residues at position 4-6 and 13 are almost invariably conserved more than 95%, this criteria was considered to select the potential ZNF143 binding sites. Finally, we found that the 83 staf binding sites of 62 genes contained these conserved C residues (Supplementary Data). This suggests that ZNF143 functions as the pivotal factor to control gene expressions for DNA repair pathways.
DNA repair-associated gene expression regulated by ZNF143 We found that Rad51 and flap endonuclease-1 (FEN-1) had putative ZNF143 binding site in the core promoter region as shown in Figure 6a and Supplementary Data. We carried out Western blotting analysis. As shown in Figure 5a , both cellular Rad51 and FEN-1 proteins were upregulated in cisplatin-resistant cells. Reciprocally, cellular Rad51 and FEN-1 proteins were decreased when PC3 cells were treated with ZNF143 siRNA (Figure 5b ). To determine whether ZNF143 directly RNA promoter by p73. Purified GST or GST-p73 (50, 250 and 500 ng) were mixed with GST (100 ng) or purified GST-ZNF143 (100 ng), and incubated with 32 P-labeled U6 RNA oligonucleotides containing ZNF143 binding site. The reaction mixtures were resolved by electrophoresis on a 4% polyacrylamide gel with 0.5 Â TBE buffer. The gel was dried and analysed by a bio-imaging analyzer (FLA2000). (b) Enhancement of ZNF143 binding to cisplatin-modified DNA by p73. Purified GST-p73 and GST-ZNF143 were incubated with 32 P-labeled cisplatin-modified DNA (GC-Pt), and EMSA was performed by the same method as described in (a). 
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promoter enrichment was observed when unrelated peroxiredoxin 4 (PRDX4) gene promoter was assayed.
We next performed ChIP assay and reporter assay with transient transfection to gain greater insight into the transcriptional regulation of two DNA repair genes. PC3 cells were co-transfected with the reporter plasmid driven by the promoter of Rad51 or FEN-1 genes with p73 expression plasmid. These promoter regions contain ZNF143 binding site. p73 activated both promoter activities ( Figure 7a) .
Next, we determined whether p73 expression induced by cisplatin treatment enhances the ZNF143 binding to the promoter of these DNA repair genes. We have previously shown that ZNF143 expression was also induced by cisplatin treatment as well as p73 (Ishiguchi et al., 2004; Uramoto et al., 2002) . Thus, we employed the stable transfectant for ChIP assay to avoid the effect of the enhanced expression of endogenous ZNF143 by cisplatin treatment on the binding to the promoters. We assessed the effect of cisplatin treatment on p73 expression in PC3 cells. p73 expression by cisplatin treatment was substantially increased relative to untreated control cells (data not shown).
ChIP assay demonstrated that the promoter sequence of both DNA repair genes was concentrated in the immunocomplexes prepared after cisplatin treatment (Figure 7b , lanes 5 and 6). Collectively, these results show that the expression of two DNA repair genes is mediated, at least in part, by ZNF143 binding stimulated by p73 expression after cisplatin treatment.
Discussion
We have previously reported that ZNF143 is induced by cisplatin treatment and that it binds preferentially to cisplatin-modified DNA (Ishiguchi et al., 2004) , suggesting that it plays an important role in cisplatin resistance. In the present study, we found that ZNF143 interacts with p73 and is directly involved in cisplatin sensitivity through the regulation of DNA repair gene expression.
ZNF143 is overexpressed at both mRNA and protein levels in cisplatin-resistant cells (Figure 1) . Interestingly, an increase in ZNF143 protein was observed when the total nuclear fraction of cisplatin-resistant cells was analysed (Figure 1b ), but not when nuclear protein eluted with salt buffer was loaded (data not shown). This indicates that ZNF143 binds tightly to cisplatinmodified chromatin and could not be eluted easily under low salt condition.
Functional analysis of ZNF143 provides considerable insight into the epigenetics of cisplatin-resistance and might be of use in revealing targets for overcoming drug resistance. ZNF143 depletion using siRNA confers cell sensitivity to cisplatin, but not to oxaliplatin, etoposide and vincristine (Figure 2b ). Further, downregulation of ZNF143 could partially reverse the cisplatin resistance of P/CDP6 cells (Figure 2c and d) . It is noteworthy that ZNF143 does not affect cellular sensitivity to oxaliplatin, which is a third-generation platinum drug that has shown a lack of cross-resistance with cisplatin (Raymond et al., 2002) . We previously demonstrated that etoposide can induce ZNF143 expression (Ishiguchi et al., 2004) , but the current results suggest that upregulation of ZNF143 by etoposide treatment is not directly involved in etoposide sensitivity. ZNF143 might, however, be involved specifically in DNA repair following DNA damage by cisplatin.
Co-immunoprecipitation assay showed that the tumor suppressor gene product p73 interacts with ZNF143. We previously reported that p53 interacts with high mobility group box 1 (HMGB1) and stimulates the binding of HMGB1 to cisplatin-modified DNA (Imamura et al., 2001) . We therefore investigated whether p73 plays a similar role and found, using EMSA, that p73 enhances the cisplatin-modified DNA binding of ZNF143 (Figure 4b ). We could not detect a p73 supershift, suggesting that although p73 stimulates ZNF143 binding to cisplatin-modified DNA, it cannot interact stably during electrophoresis. p73 overexpression is associated with resistance to DNA-damaging agents (Vikhanskaya et al., 2001) , so both ZNF143 and p73 might be cooperatively involved in cisplatin resistance. p73 also enhances the ZNF143 binding to its binding site located in the promoter region of human U6 RNA gene. As both p73 and ZNF143 expression are induced by DNA damage signal, p73 might function cooperatively to activate the ZNF143 target gene expression. Little is known about potential ZNF143 target genes for DNA repair pathways. Among several DNA repair pathways, it has been extensively studied that excision repair crosscomplementation group 1 (ERCC1) has the critical role in nucleotide excision repair pathway and high ERCC1 ZNF143 and cisplatin resistance T Wakasugi et al expression is associated with cisplatin resistance (Altaha et al., 2004) . Both BRCA1 and Rad51 have been shown to be involved in recombinational repair and also associated with cisplatin resistance (Bhattacharyya et al., 2000; Spiro and McMurray, 2003) . The FEN-1 is a 5 0 endonuclease and has been implicated in various DNA repair processes (Lieber, 1997) . Based on these reports, we searched putative ZNF143 binding site in the promoter region of these DNA repair genes and found that putative ZNF143 binding sites are located in the core promoter region of these genes. We confirmed the role of ZNF143 in the regulation of both Rad51 and FEN-1 gene expression by three independent approaches: siRNA strategy, EMSA and ChIP assay as shown in Figures 5b, 6b and d, respectively. In addition, p73 transactivated the promoter activities of two DNA repair genes (Figure 7a ) and cisplatin treatment resulted in the enhanced binding of ZNF143 to these promoters (Figure 7b) . Thus, p73 interacts with ZNF143 and modulates its function, and therefore has the potential to broadly regulate the DNA repair gene expression.
We also carried out a search of the sequence database to identify the distribution of the ZNF143 binding sites of all DNA repair genes. Surprisingly, we found that a 3) were amplified by PCR using specific primer pairs for the Rad51, FEN-1 and PRDX4 promoter regions. Amplification products (682 bp for Rad51, 844 bp for FEN-1 and 157 bp for PRDX4) were separated by electrophoresis on a 2% agarose gel and stained with ethidium bromide. The arrowhead indicates amplified PCR fragment containing the promoter region of gene.
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number of DNA repair genes contain potential binding site for ZNF143 in their regulatory regions (Supplementary Data). These results suggest that ZNF143 is a positive regulator like a master gene for the expression of DNA repair genes.
In conclusion, our data indicate that ZNF143 is a pivotal transcription factor that regulates the gene expression for DNA repair pathways together with p73 and is involved in cisplatin resistance. Our findings also raise the possibility that inhibition of ZNF143 function might be a target for therapeutic augmentation of cisplatin-based chemotherapy. Further investigation to define the molecular function of ZNF143 will greatly advance our understanding of cisplatin resistance.
Materials and methods
Cell culture
Human epidermoid cancer KB cells and human prostate cancer PC3 cells were cultured in Eagle's minimal essential medium (Nissui Seiyaku, Tokyo, Japan) containing 10% heatinactivated fetal bovine serum. The cisplatin-resistant KB/CP4 and P/CDP6 cells were derived from KB and PC3 as described previously (Tanabe et al., 2003) . Seven lung cancer cell lines were obtained as described previously (Sugaya et al., 2002) . Cell lines were maintained in a 5% CO 2 atmosphere at 371C.
Antibodies and drugs
Anti-Flag (M2) monoclonal antibody and anti-Flag (M2) affinity gel were purchased from Sigma (St Louis, MO, USA). Anti-STAT3 (sc-482), anti-proliferating cell nuclear antigen (PCNA) (sc-56) and HA-probe (F-7) AC (agarose conjugate) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Rad51, anti-FEN-1 antibodies and anti-HAperoxidase (3F10) were purchased from Calbiochem (Darmstadt, Germany), BD Biosciences (BD Biosciences Clontech, Palo Alto, CA, USA) and Roche molecular Biochemicals (Mannheim, Germany), respectively. The anti-ZNF143 antibody was kindly gifted by Dr GR Kunkel (Texas A&M University, TX, USA) (Ishiguchi et al., 2004) . Cisplatin, vincristine and etoposide were purchased from Sigma. Oxaliplatin was kindly provided from Yakult Honsha Co., Ltd., Tokyo, Japan.
Plasmid construction
Plasmid construction of pGEX-p53, pGEX-p73 and pGEX-ZNF143 that express GST-p53, GST-p73 and GST-ZNF143 proteins in bacteria, respectively, and pcDNA3-HA-p53 that expresses HA-p53 protein in mammalian cells were described previously (Imamura et al., 2001; Uramoto et al., 2002 Uramoto et al., , 2003 . pcDNA3-HA-p73 expression plasmid in mammalian cells was kindly provided by Dr G Melino (University of Rome, Rome, Italy) (De Laurenzi et al., 1998) . For construction of pcDNA3-3 Â Flag expression plasmid, the following doublestranded oligonucleotides were inserted to pcDNA3 expression plasmid (Invitrogen, San Diego, CA, USA) between BamHI and EcoRI sites. Three times Flag oligonucleotides; 5 0 -ATGGACTACAAAGACCATGACGGTGATTATAAAGAT CATGACATCGATTACAAGGATGACGATGACAAGAAT TGG-3 0 . To obtain the pcDNA3-3 Â Flag ZNF143, full length of ZNF143 cDNA was ligated at C-terminal of 3 Â Flag in pcDNA3-3 Â Flag mammalian expression plasmid. For construction of pIRES/hygro-3 Â Flag ZNF143, BamHI-NotI fragment containing 3 Â Flag ZNF143 was obtained by digesting the pcDNA3-3 Â Flag ZNF143 plasmid with BamHI and NotI, and ligated in same sites of pIRES/hygro mammalian expression plasmid (BD Biosciences Clontech). To obtain Rad51 Luc and FEN-1 Luc, Rad51 and FEN-1 promoters were amplified by polymerase chain reaction (PCR) with the following primer pairs with restriction enzyme cleavage sites at the 5 0 end; 5 0 -AGATCTGCGATGGTGAGAACTCGCGGA CC-3 0 and 5 0 -AAGCTTCACCCCGCGGGCGTGGCACG-3 0 for the Rad51 promoter (À471 to þ 211); 5 0 -AGATCTGTA-CAGAGGCTGTGGGCGCTCC-3 0 and 5 0 -AAGCTTGGTT CGGGGTTGCCCCGGGC-3 0 for the FEN-1 promoter (À525 to þ 319). These PCR products were cloned into the pGEM-T easy vector (Promega, Madison, WI, USA). The promoter fragments were gel-purified after BglII-HindIII digestion and ligated into the BglII-HindIII site of pGL3-basic vector (Promega).
Cloning of stable transfectants
Two micrograms of pIRES/hygro vector or pIRES/hygro-3 Â Flag ZNF143 was transfected into 1 Â 10 5 cells of PC3 using 10 ml Superfect reagent (Qiagen, Hilden, Germany) according to the manufacturer's instructions. After 24 h of transfection, the cells were trypsinized and plated on 100-mm dishes with dilution to form colonies and cultured with maintenance medium containing 250 mg/ml hygromycin. The resulting colonies were isolated using cloning cylinders and transferred to 24-well plates. Cellular expression level of 2) were amplified using specific primer pairs for the Rad51 and FEN-1 promoter regions. Amplification products were subjected by electrophoresis as described in Figure 6d .
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Northern blotting
Northern blotting analysis was performed as described previously (Murakami et al., 2001; Ishiguchi et al., 2004) . Briefly, total RNA was isolated using the Sepasol reagent (Nacalai Tesque, Kyoto, Japan). RNA samples (20 mg/lane) were separated on a 1% formaldehyde agarose gel and transferred to a hybond N þ membrane (GE Healthcare BioScience, Piscataway, NJ, USA) with 10 Â SSC. ZNF143 cDNA fragments were labeled with random primers using the Megaprime DNA labeling kit (GE Healthcare Bio-Science). After prehybridization and hybridization, signal intensities were quantified using a bio-imaging analyzer (FLA2000, Fuji Photo Film, Tokyo, Japan).
Western blotting
Whole-cell lysates and eluted nuclear extracts were prepared as described previously (Uramoto et al., 2002) . To prepare wholenuclear protein, isolated nuclei was directly sonicated for 10 s and designated as nuclear fractions. The indicated amounts of whole-cell lysates, nuclear extracts or nuclear fractions were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred to a polyvinylidine difluoride microporous membranes (Millipore, Bedford, MA, USA) using a semi-dry blotter. The blotted membrane was treated with 5% (w/v) skimmed milk in 10 mM Tris, 150 mM NaCl, 0.2% (v/v) Tween 20 and incubated for 2 h at 41C with a 1:5000 dilution of anti-ZNF143, a 1:10 000 dilution of anti-Flag (M2), a 1:2000 dilution of anti-PCNA, a 1:1000 dilution of anti-STAT3, a 1:500 dilution of anti-FEN-1 and a 1:1000 dilution of antiRad51 antibodies. The membrane was then incubated for 40 min at room temperature with a peroxidase-conjugated secondary antibody or a 1:5000 dilution of anti-HA-peroxidase. It was treated with an ECL kit (GE Healthcare BioScience) and exposed to Kodak X-OMAT film by autoradiography. The intensity in each signal was assessed numerically by NIH image program (NIH, Bethesda. MD, USA).
Transient transfections and co-immunoprecipitation assay
Transient transfection and immunoprecipitation assay were performed as described previously (Uramoto et al., 2002; Izumi et al., 2003) . Briefly, 1 Â 10 5 PC3 cells were seeded into six-well tissue-culture plates. The following day, both 1 mg HA and 3 Â Flag expression plasmids were transfected using Superfect reagent (Qiagen) according to the manufacturer's instructions. Three hours post-transfection, the cells were washed with phosphate-buffered saline, cultured at 371C for 48 h in fresh medium and then lysed in buffer X containing 50 mM Tris-HCl (pH 8.0), 1 mM ethylenediaminetetraacetic acid (EDTA), 120 mM NaCl, 0.5% Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride and 1 mM ZnCl 2 . After incubating for 30 min on ice, the lysates were centrifuged at 21 000 g for 10 min at 41C. The supernatant (300 mg) was incubated for 2 h at 41C with anti-Flag M2 affinity gel or HAprobe (F-7) AC, and the beads were washed three times with buffer X. Immunoprecipitated samples and pre-immunoprecipitated samples (50 mg) were separated by SDS-PAGE, and Western blotting analysis was performed with anti-Flag antibody and anti-HA-peroxidase as described above.
Knockdown analysis using siRNAs Three kinds of double-stranded ZNF143 RNA 25 bp oligonucleotides were generated from Stealth Select RNAi (Invitrogen) 0 . siRNA transfections were performed according to the manufacturer's instructions (Invitrogen). Briefly, 1 ml lipofectamine transfection reagent (Invitrogen) was diluted in 250 ml Opti-minimum essential medium (MEM) I medium (Invitrogen) and incubated for 5 min at room temperature. Next, 50 or 100 pmol ZNF143 siRNA and Stealth RNAi negative control with medium GC (Invitrogen) diluted in 250 ml Opti-MEM I were added gently and incubated for 20 min at room temperature. Oligomer-Lipofectamine complexes and aliquots of 2 Â 10 5 PC3 or P/CDP6 cells in 2 ml culture medium were combined and incubated for 10 min at room temperature. Aliquots of 4 Â 10 2 PC3 cells or 6 Â 10 2 P/CDP6 cells were used for a colony-formation assay as described below. The remaining cells were seeded in 35 mm dishes with 2 ml culture medium and harvested after 72 h culture for Western blotting analysis as described above.
Cytotoxicity assay
For the colony-formation assay, 4 Â 10 2 PC3 or 6 Â 10 2 P/ CDP6 cells transfected with siRNAs were seeded in 35 mm dishes with 2 ml culture medium. The following day, the cells were treated with indicated concentrations of cisplatin, oxaliplatin, etoposide and vincristine. After 7 days, the number of colonies was counted.
Purification of GST fusion protein Induction and purification of GST fusion proteins were described previously (Ise et al., 1999) . Briefly, Escherichia coli cells transformed with GST expression plasmids were induced by isopropyl-1-thio-g-D-galactopyranoside for 1 h and sonicated for 10 s in buffer X as described above. Soluble fractions were obtained by centrifugation at 21 000 g for 10 min at 41C. GST fusion proteins were bound to 10 ml glutathionesepharose 4B in a 50% slurry in buffer X for 4 h at 41C, washed three times with buffer X and eluted with 50 mM TrisHCl (pH 8.0) and 20 mM reduced glutathione according to the manufacturer's protocol (GE Healthcare Bio-Science).
Electrophoretic mobility shift assay
The sequences of the oligonucleotides used for the probes in EMSAs were as follows: human U6 RNA oligo, 5 0 -GCC TATTTCCCATGATTCCTTCATATTTGC-3 0 and 5 0 -GGGC AAATATGAAGGAATCATGGGAAATAGG-3 0 ; human Rad51 oligo, 5 0 -GGTACATCTCCCGGCATGCATCGCCG GCG-3 0 and 5 0 -GGCGCCGGCGATGCATGCCGGGAGAT GTA-3 0 ; human FEN-1 oligo, 5 0 -GGACCCGTGCCCATCC TACAATGCCCTGG-3 0 and 5 0 -GGCCAGGGCATTGTAG GATGGGCACGGGT-3 0 ; GC oligo for modification of cisplatin, 5 0 -GGCCGGGGCGGGGCGATCGGGGCGGGGGC-3 0 and 5 0 -GGGCCCCCGCCCCGATCGCCCCGCCCCGG. The ZNF143 binding sites in these oligonucleotide probes were underlined (see Figure 6a) . Preparation of the 32 P-labeled oligonucleotide probes were described previously (Imamura et al., 2001; Ishiguchi et al., 2004) . Briefly, the oligonucleotides were annealed with complementary strands. The doublestranded products were end-labeled with [a-
32 P] deoxycytidimine triphosphate (GE Healthcare Bio-Science) using the ZNF143 and cisplatin resistance T Wakasugi et al Klenow fragment (Fermentas, Vilnius, Lithuania) and purified from gel. For preparation of cispaltin-modified DNA, labeled GC oligonucleotide probe was treated with 0.3 mM cisplatin at 371C for 6 h and purified by ethanol precipitation. EMSAs with purified GST fusion proteins were performed as described previously (Imamura et al., 2001; Ishiguchi et al., 2004) . Briefly, GST fusion proteins were incubated for 5 min at room temperature in a final volume of 20 ml containing 10 mM TrisHCl (pH 7.5), 50 mM NaCl, 5 mM MgCl 2 , 10 mM ZnCl 2 , 1 mM EDTA, 1 mM dithiothreitol, 0.1 mg/ml bovine serum albumin, 10% glycerol, 0.05% Nonidet P-40 and 4 ng 32 P-oligonucleotide probe. The reaction mixtures were resolved by electrophoresis on a 4% polyacrylamide gel (polyacrylamide/ bisacrylamide, 80:1) by 10 V/cm for 90-120 min at room temperature with 0.5 Â tris-borate-EDTA (TBE) buffer (45 mM Tris base, 45 mM boric acid and 1 mM EDTA). The gel was dried and analysed by a bio-imaging analyzer (FLA2000).
ChIP assay
The ChIP assay was performed as described previously (Uramoto et al., 2002) . Both PC3/CV and PC3/3FZ stable transfectants were treated with or without 20 mM cisplatin for 12 h. Briefly, protein-DNA crosslinking was performed by incubating PC3/control vector and PC3/3 Â Flag-ZNF143 cells with formaldehyde. The cells were lysed in radioimmunoprecipitation assay buffer (50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40 and 1 mM phenylmethylsulfonyl fluoride) and the lysates were sonicated. Soluble chromatin from 1 Â 10 6 cells was incubated with 5 mg/ml anti-Flag (M2) affinity gel or anti-mouse immunoglobulin G (IgG) with protein A/G agarose (Santa Cruz) by rotation for 2 h at 41C. Immune complexes were collected by centrifugation. They were then treated with 0.2 M NaCl to reverse protein-DNA crosslinking, and were digested with proteinase K and RNase A. The purified DNA was dissolved with 20 ml dH 2 O. The DNA (1 ml) was then used for PCR analysis with the following primer pairs for the Rad51 promoter region ( Transient transfection and luciferase assay Transient transfection and a luciferase assay were performed as described previously (Uramoto et al., 2002) . Briefly, 5 Â 10 4 PC3 cells were seeded into 12-well tissue-culture plates. The following day, 0.2 mg of Rad51 or FEN-1 reporter plasmid was transfected with 1.2 mg of p73 expression plasmid using 3 ml/well Superfect reagent (Qiagen) according to the manufacturer's instructions. Three hours post-transfection, the cells were washed and cultured at 371C for 48 h in fresh medium. Luciferase activity using cell lysated with lysis buffer and brief centrifugation was detected by a Picagene kit (Toyoinki, Tokyo, Japan), and the light intensity was measured with a luminometer (Luminescencer JNII RAB-2300; ATTO, Japan) according to the manusfacturer's instructions. 
ZNF143 binding site analysis
